Absci (NASDAQ:ABSI) recently achieved a few milestones in healthcare AI as it received a $20 million investment from AMD to support Absci’s AI-driven drug discovery initiatives. In addition, the ...

For that reason, every attempt by an AI drug to get approval is a landmark of sorts. Tuesday, drug development startup Absci, based in Vancouver, Washington, announced such a landmark, the ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery and design of novel therapeutics. Absci, known for its generative AI in drug ...

Absci Corporation reported significant advancements in its proprietary AI-driven drug creation platform during its 2024 R&D Day. The company entered into a $20 million strategic collaboration with ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street's Radar. In this article, we are going to take a look at where Absci Corporation (NASDAQ:ABSI) stands against the other ...

VANCOUVER, Wash. and PARIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to ...

Absci, which engineers biologic drugs based on its own generative AI platform, has advanced its lead candidate into the clinic by dosing the first healthy volunteers in a trial designed to assess ...

On Monday, cancer research giant Memorial Sloan Kettering and life sciences AI pioneer Absci announced a first-of-its kind partnership to discover six novel therapies for cancer using generative ...

The goal of both of these entities is to combine their expertise to generate 6 programs using the generative AI approach. Absci is to provide its Integrated Drug Creation Platform, while MSK is ...

Absci Corp., a Vancouver, Wash.-based company that uses AI to develop drugs, is partnering with Memorial Sloan Kettering Cancer Center to create up to six novel cancer therapeutics using ...

“Absci is the first and only company to design and validate new antibodies with a zero-shot generative AI,” McClain told a room of investors. “We’re doing this all from scratch on a compute ...

I think it's leveraging AI." Sean McClain, founder and CEO of Absci, and Christian Stegmann, SVP of Drug Creation, sit down with Andrew Galler to discuss Absci's generative AI platform and ...